Neil Riordan PhD

Professional Site

  • Scientific Articles
  • Abstracts
  • Stem Cell Research
    • Heart Disease
    • Lupus
    • Mesenchymal Stem Cells
    • Pulmonary
  • Intellectual Property
  • Book Chapters
  • Invited Reviewer
  • Awards
Home Stem Cell Research Mesenchymal Stem Cells

Mesenchymal Stem Cells

New article presents data on safety of mesenchymal stem cells.

Safety of Mesenchymal Stem Cells for Clinical Application

Key points:

There is no evidence for tumorigenicity of MSCs expanded in vitro.

The authors performed GLP-compliant in vivo toxicity studies using NOD mice,
NOD/SCID mice, guinea pigs, rabbits, and monkey models.

Subcutaneous injection of 10 million culture expanded mesenchymal cells from umbilical cord did not induce tumor formation in both NOD mice and NOD/SCID mice.

Large, 2 million and 10 million cells/kg doses were given to cynomolgus monkeys once per week for six weeks. No significant mesenchymal stem cell-related changes were found in body weights, clinical signs, hematological/biochemical values, organ weights, or histopathological findings.

The cells inhibited tumor growth in mice. “Two injections (two week interval) of different doses of UC-MSCs [umbilical cord-mesenchymal stem cells] resulted in a significant inhibition of K562 tumor growth in the mice bearing leukemic tumors.

No significant MSCs-related changes were found in body weights, clinical signs, hematological/biochemical values, organ weights, or histopathological findings.

Safety of Mesenchymal Stem Cells for Clinical Application
Youwei Wang, 1 Zhi-bo Han, 1 Yong-ping Song, 2 and Zhong Chao Han 1, 2 , *

Abstract
Mesenchymal stem cells (MSCs) hold great promise as therapeutic agents in regenerative medicine and autoimmune diseases, based on their differentiation abilities and immunosuppressive properties. However, the therapeutic applications raise a series of questions about the safety of culture-expanded MSCs for human use. This paper summarized recent findings about safety issues of MSCs, in particular their genetic stability in long-term in vitro expansion, their cryopreservation, banking, and the role of serum in the preparation of MSCs.

Neil Riordan, PhD

  • About Neil Riordan, PhD

Follow me on:

  • Facebook
  • Twitter

Recent Posts

  • Amnion-derived cells for regenerative medicine January 27, 2020
  • Vitrification preserves Wharton’s Jelly up to a year January 21, 2020
  • Adipose MSC for Spinal Cord Injury: ASIA Scores Improvement December 4, 2019
  • UCMSC secretions (exosomes) for Perinatal Brain Injury October 3, 2019
  • Immunomodulation of UCMSC in Rheumatoid Arthritis September 26, 2019

Tags

acute liver failure adipose amnion arthritis CD34 diabetes disease dmd duchenne muscular dystrophy fat Frederick Klenner liver lupus mesenchymal mesenchymal stem cells mitochondria mitochondrial neil Neil Riordan opioid opioid tolerance Panama preeclampsia pregnancy rheumatoid rheumatoid arthritis Richard Davis Humphries Richard Humphries riordan spinal cord injury stem cells umbilical cord vitamin C

Copyright © 2023 · Focus Pro Theme on Genesis Framework · WordPress · Log in